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1. ABSTRACT 
In order to determine the applicability of noninvasive magnetic resonance spectroscopy (MRS) to the 
study of a diseased tissue or organ in the human body, it is necessary to determine if MRS is safe and 
effective. This is the primary purpose of a clinical trial. A clinical trial for MRS may also reveal 
which technical approach works best for the specific application and characteristics of the population 
being studied. In this chapter, we discuss the legal, ethical, and scientific requirements to be 
considered prior to the start of a clinical trial of an MRS protocol, as well as constraints that may arise 
during its execution. MRS-specific issues arising from a couple of successful clinical MRS trials for 
classifying brain tumors with 
1
H MRS (INTERPRET and eTUMOUR) and body tumors with 
31
P 
MRS  (the Cooperative Group on MRS Application in Cancer, CoGMAC), serve as illustrative 
examples. 
 
2. INTRODUCTION 
The clinical value of MRS, like that of any other medical test, must be assessed in clinical trials (i.e. 
research studies that prospectively assign human participants into health-related interventions to 
evaluate health outcomes, conducted according to formal rules).  This chapter will discuss the issues 
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that need to be addressed when planning and conducting a clinical trial of an MRS method.  We will 
also briefly review some of the multi-center trials that have so far been performed and lessons that can 
be learned from them.  We will use examples from two multi-center studies aimed at classifying 
different brain tumor  types, INTERPRET (1)  and eTUMOUR (2), to illustrate 
1
H MRS, and one 
from the Cooperative Group on MRS Application in Cancer (CoGMAC), which performed several 
trials on patients of non-Hodgkin’s lymphomas (NHL), sarcomas of soft tissue and bone, breast 
carcinomas and head and neck carcinomas, to illustrate 
31
P MRS (3,4). 
3. METHODS USED IN CLINICAL TRIALS OF MRS 
3.1. Preliminary considerations 
A clinical trial of an imaging method must be conducted according to formal rules.  Trials 
that do not follow such rules will be unlikely to meet the criteria for inclusion in the 
Evidence Based Medicine meta-analyses that are nowadays used to decide whether a new 
technique should be adopted or an old technique should be dropped. For instance, a study 
intended to demonstrate diagnostic accuracy of a novel method (the most common potential 
use for MRS) should follow the 25 criteria set out in the STARD initiative (STAndards for 
the Reporting of Diagnostic accuracy studies) (5).  
 
Historically, very few published clinical MRS studies were designed to adhere to criteria 
such as STARD, or even to be formal clinical trials.  Furthermore, most were performed at a 
single center on a small number of patients and thus were therefore lacking in statistical 
power.  When formal meta-analyses of the clinical MRS literature were performed (reviewed 
by (6)) few of the many thousands of published clinical MRS  papers were qualified for 
analysis, and those that met the Evidence Based Medicine criteria had often been performed 
on small groups of patients, or with earlier generation instruments.  Consequently, MRS 
appeared to perform badly in the meta-analysis, and that poor performance eventually 
resulted in the denial of reimbursement for MRS (CPT 76390) across hundreds of healthcare 
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providers in the USA (see (6)).  Table 1 shows a set of criteria devised by (6) that should be 
followed if a trial is to be included in future EBM meta-analyses.  
Table 1 near here 
3.2. Logistical challenges 
In a clinical trial of a medical device such as MRS, the patients studied should have specific 
health conditions under clearly defined treatments. This requirement can be difficult to 
satisfy. First, the definition of the health condition may change, or it could become subdivided 
into two or more conditions. Similarly, a treatment considered the standard for a disease could 
be changed during the trial for another that has proven to be more effective. A clinical trial of 
a device cannot control such changes in medical practice, which may be adopted at different 
times (or not at all) by the clinicians in the various collaborating centers. 
Furthermore, in any multi-institutional clinical trial the logistical challenges related to time, 
costs, patient tolerance, and involvement of personnel must be taken into account in the 
project-planning phase.  In addition, international cooperation for a trial adds another level of 
complexity due to differences in the standards for diagnosis and treatment in each country. 
The numbers of patients and MRI/MRS acquisitions must be clearly estimated and the time 
frames for accrual as well as the planning for subsequent follow-up should be kept as short as 
possible. Further, the inclusion of medical centers should be based not only in the hospital’s 
ability to perform the protocol but also in its ability to recruit patients, taking into account the 
incidence rate of this particular disease and the population covered by the hospital involved.  
Similarly, magnetic resonance (MR) technology including MRS has evolved in large strides 
in the past two decades. For many years clinical trials were performed using the standard 
clinical magnetic field strength of 1.5 Tesla, but in the past 10 years 3.0 Tesla clinical MR 
scanners have become widely available and for the past five years whole-body MR scanners 
at 7.0 Tesla have been tested in major clinical centers. Furthermore, other types of hardware 
(i.e., single vs. phased-array coils) and software (i.e., single volume vs. multivolume 
acquisitions; or the use of echo-planar algorithms to acquire MRS) continue to advance. An 
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informed decision should be made every time such technological advances become available 
in the middle of a clinical trial of MRS. One needs to evaluate carefully the benefits offered 
by the new technology against the requirements needed to test it, to adapt the trial to use it 
properly, and to properly combine the new data with the data acquired with the previously 
available technology.  As with any medical advances, however, the managers of the trial may 
have little or no control over the adoption of technical improvements at the different 
collaborating centers. 
In addition, plans must also be made for collection of additional data, such as clinical 
information, genomic data, images or reports from other imaging modalities or biopsies. If 
biological specimens (biopsies, fluids, blood) have to be collected, it is inevitable that 
collection will fail in some instances. The more data types and controls we want to collect, the 
less probable is that we will be able to collect matched datasets for all the types of 
information. For example, the eTUMOUR project collected data from 1317 patients, of whom 
656 fulfilled the minimum requirements in terms of data availability, 470 fulfilled the quality 
requirements, and 289 fulfilled the clinical validation requirements. Only 222 cases fulfilled 
all three requirements at the same time (2).  
The number and type of quality control (QC) procedures should be estimated as precisely as 
possible in any multicenter trial and particularly in an international one. Are these QC 
procedures already in place at all institutions or will they need to be developed and 
validated? Who will do that development and how long will it take? It is also important that 
all the crucial tasks should be performed by personnel who are under the control of the 
project’s management. In a multidisciplinary patient evaluation, for instance, a study may 
have one consent form for the biopsy and another one for the MRS acquisition – both 
consents should be obtained by project personnel. If we are not planning a clinical trial 
managed by a contract research organization (CRO), enough trained human resources should 
be committed. Many important tasks in the study, such as development of a database, are not 
“scientific” but can still take years. Development and training time frames must be estimated 
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as realistically as possible.  In an ideal world all the participating staff would receive uniform 
training in the procedures to be used; in reality that is almost never possible because of time 
and financial constraints. 
  
3.3. Legal regulations 
Clinical trials are of course, subject to the laws of the country in which they are performed, 
and again multicenter trials performed in more than one country are made more complex 
because they have to obey several legal frameworks. For example, when the MRS files have 
to travel outside the originating clinical center for analysis, or to a database, they must be 
anonymized or de-identified by stripping any data allowing identification of the patient or 
volunteer. Anonymization was traditionally a bottleneck in clinical trials of MRS until the 
advent of the DICOM MRS formats, although even today some MRS vendors (e.g. General 
Electric) have not yet moved to the DICOM standard. 
One of the most important legal steps is when the clinician or academic researcher in charge 
(who in some countries will be the medical doctor responsible for the patient, not the 
academic researcher) must seek approval from the local Ethics Committee or Institutional 
Review Board (IRB). That obtained, the study can then start recruitment of patients, each of 
whom must give informed consent. Patient consent involves two documents: the information 
sheet and the consent certificate, the latter must be signed by the patient or his/her legal 
representative. Both documents must be written in language understandable to the patient, 
and must be stored by the clinician in charge at the clinical center where the medical 
procedure is carried out. In the US an additional document relating to confidentiality is also 
signed at the time of consent.  
When a multicenter, international trial is conducted, the items that will appear on the 
information sheet must be agreed among the participating centers and then adapted to the 
national languages and standard forms of the participating hospitals and countries. In 
addition and to maintain uniformity, research centers participating in international research 
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funded by federal institutions in the US must follow the rules and regulations of the US 
funding institution, even if the regulations in the country concerned are different. 
 
3.4. Consensus protocols 
Consensus protocols for acquisition, processing and validation will be required for the MRS 
methods as well as for the additional data that are to be acquired by the study.  As a general 
rule, it is better to use “standard of care” rather than “state of the art” acquisition protocols, 
unless, of course, the aim of the trial is to test a state of the art protocol. Standard of care 
protocols can be more easily adopted by (or may be already in use in) many possible 
contributing centers, and it may also be possible to obtain retrospective data for pilot studies, 
so as to increase the numbers of data from uncommon medical conditions. However, a lot of 
MRS techniques are not standard of care. In the US, the only MRS modality that has reached 
standard of care level is 
1
H MRS obtained using single voxel spectroscopy. This means that 
obtaining multivolume (MV) 
1
H MRS (usually using the chemical shift or the Hadamard 
algorithms) and all types of non-
1
H MRS (usually referred as multinuclear MRS) like 
31
P or 
13
C MRS are considered non-standard of care and their use adds to the complexity of the trial 
and difficulty of finding institutions with the proper infrastructure to acquire them. 
 
3.4.1. Acquisition Protocols 
To minimize variability, most MRS trials have studied only one protocol (3,7) and/or, used a 
single scanner model (7). This restricts the number of potential participating centers and may 
not allow recruitment of enough cases with rare medical conditions. One solution, adopted by 
the INTERPRET project, is to define “compatible acquisition protocols” (Table 2), by 
performing pilot studies. For example, in (1), using a retrospective set of patients with brain 
tumors who had been studied using single voxel (SV) 
1
H MRS at 1.5T,  it was found that 
spectra obtained by different sequences (STEAM and PRESS), different echo times (TE; 20, 
30, 31, and 32 ms), two different repetitions times (TR; 1600 and 2000 ms), and two scanner 
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brands (GE and Philips) were still compatible for a pattern recognition (PR) study that aimed 
to classify common brain tumor types.  
Table 2 near here 
In (3,4) the standardization and QC protocols set-up for a trial to use the MV (3D) acquisition 
of 
31
P MRS at 1.5 Tesla to study patients with several forms of cancer (mainly lymphomas 
and sarcomas) were described. Even though two scanner brands were used (GE, Siemens) in 
an international multicenter study, reproducibility was optimized by using standard protocols 
and a common radio-frequency coil design. Quality control studies were performed by 
studying leg or thigh muscles of healthy human volunteers.  
3.4.2. Processing Protocols 
The spectra must be processed uniformly, using a single program and set of processing 
parameters, as shown in Table 3 for SV 
1
H MRS, or as described in (3) for MV 
31
P MRS. 
Table 3 and  
 
Figure 1 show how automatic processing followed by data storage in a central database also 
allows calculation of parameters such as signal-to-noise ratio (SNR) or water linewidth for 
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QC purposes, provides visualization software for the processed spectra and facilitates 
traceability of the MRS records. A disadvantage of automatic processing is the inevitable 
small percentage of lost data, as some spectra may be unusable without additional processing 
steps that are not included in the consensus protocol. 
Table 3 near here 
Figure 1 near here 
Finally, the set of processing parameters must also include a common output format, such as 
the INTERPRET data manipulation software and canonical format (8), which has been 
adopted by some subsequent 
1
H MRS trials (eTUMOUR and HealthAgents) (9). The 
particular feature of this canonical format is that each spectrum will have the same number of 
points along the ppm range, i.e. the same spectral resolution, which is particularly important 
when dealing with data obtained on several different scanner brands (8).  
Although the spectra were processed manually using a proprietary program, the 
31
P MRS trial 
in cancer (3,4) also used a standard set of processing parameters and a canonical format for 
the spectra. 
An additional problem is normalization, particularly in pattern recognition (PR) studies where 
we are comparing differences in the relative proportions of multiple intensities, rather than 
quantifying the absolute areas of peaks. A simple approach to intensity normalization that has 
provided good results in several PR studies, is the Euclidean or  𝑙2 norm (10), which is 
obtained by dividing the value of each individual point by the value of the norm. The norm is 
obtained by squaring the value of each point in the spectral vector, adding all them and taking 
the square root of this sum. The value of each point is then divided by the norm. This yields 
comparable spectra, without the need to take into account the water content of the tissue or 
the number of acquisitions, provided that all the spectra have the same number of points - 
hence the importance of a canonical format with standardized spectral resolution.  
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A different approach for normalization was introduced in the MV 
31
P MRS trial in cancer. In 
this case, for QC as well as for quantification and normalization purposes, a glass sphere of 
about 2 milliliters was placed in the center of the radiofrequency coil with a known solution 
of triphenylphosphite (TPP) that has a 
31
P signal with a T1 value below 0.2 seconds.  These 
standards were custom-made from the highest purity reagent available (Sigma Chemical Co., 
St. Louis, MO, USA). The 
31
P signal of TPP resonates approximately 3500 Hz away from the 
in vivo signals at 1.5 Tesla, allowing acquisition of its signal without affecting the in vivo 
results. The 90
0 
excitation pulse for TPP was calculated and using a TR of 1 second a fully-
relaxed spectrum of 64 excitations was acquired for each human study. The area of the signal 
of TPP was integrated and its value used to normalized the in vivo signals (4). 
3.4.3. Validation 
Regular instrumental QC studies should be performed on phantoms and normal volunteers to 
ensure that each spectrum will have adequate SNR, good spectral resolution and absence of 
artifacts (3,4,11). In addition, every spectrum used for analysis should undergo an individual 
check, either by experts using standard criteria (4) or by PR algorithms using criteria 
previously set by experts (11,12). For example, the INTERPRET project used a PR approach 
on a subset of spectra to determine empirical thresholds for SNR and water linewidth; these 
thresholds were subsequently used for expert-based QC of individual spectra, both in 
INTERPRET and eTUMOUR (Table 4). If this semi-automated approach cannot be applied, 
which happened with the MV data in the INTERPRET project, the QC must be expert-based, 
using images of the data processed locally with the scanner software, and entered ad-hoc into 
the database by the data providers, along with relevant metadata such as field strength, 
sequence name, and the TE, TR, and voxels encoded for the X, Y and Z directions. The 
criteria for evaluation can be checked on Table 4. Manual data upload requires a significant 
input both from the data uploaders and the expert evaluators, and in the eTUMOUR project 
that resulted in a larger percentage of the manually uploaded MV spectra not completing their 
validation (65% of 613 spectra) as compared to SV (only 4.5% of 1653 spectra), in which 
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uploads were semi-automated.  The eTUMOUR project also used HRMAS (high-resolution 
magic-angle spinning) spectra from brain tumor biopsies, and their QC was also entirely 
expert-based (Table 4), resulting in a wastage of 86% of the 1348 spectra because they did not 
have their QC completed. In contrast, microarray data upload was totally automated and only 
0.3% of 665 cases were without a complete QC. These examples show how lack of 
automation could affect the validation of the massive amounts of data accrued in big 
multicenter trials.  
Table 4 near here 
The analysis of the 
31
P MRS trial on human cancer has shown good reproducibility of the data 
acquired from different institutions (3) despite of being done without automation. In it,  
principal component analysis (PCA), was used instead of quantification to automate the 
analysis (13-15) processing and analysis of the 
31
P MRS of non-Hodgkin lymphomas (NHL) 
(16). An advantage of this approach is that it does not require prior knowledge, but the 
approach is not suitable for datasets which contain spectra acquired under very different 
conditions (instruments, number of points in the FID, spectral bandwidth, etc.) (14). 
 
The position of the volume or region of interest (ROI) must be verified and should accurately 
correspond with diagnostic or outcome variable information. In the case of single-voxel 
studies, accuracy needs to be ensured at the time of acquisition. Moreover, even though the 
volume selected might be correct, chemical shift displacement (see emrstm1481) may be a 
problem for SV as well as MV acquisitions that employ selective-excitation gradients in one 
or more dimensions (16). Thus voxel or ROI location must be carefully monitored: tumors are 
heterogeneous and, for instance, the spectrum will change if we acquire data from a nodular, 
cystic or edematous part of a brain tumor (Figure 3Error! Reference source not found.).  
Figure 3 near here 
11 
 
MV acquisitions employing phase-encoding gradients are essentially devoid of this signal 
localization dependence on frequency in the phase-encoding dimensions, but more 
importantly allows the acquisition of signals from a large number of locations in a 2- or 3-
dimensional volume, usually in a similar amount of time to single-volume techniques; 
furthermore, the location of the volume or region of interest can be readily adjusted after 
acquisition.(17) 
Another source of data loss is disagreement among expert histopathologists and other 
clinicians, who provide the gold standard for diagnosis and characterization of the disease 
(18). This can cause a significant drop in the number of cases available (2,19): in 
INTERPRET about a third of the cases did not have an agreed histopathological diagnosis 
submitted. A similar number of cases were lost due to lack of clinical information in the 
31
P 
MRS trial of human cancers (4) .   
In general terms, the more we can automate all aspects of validation the better, as it saves 
time and prevents both bottlenecks and expert bias. Centralized expert review should be 
avoided if possible, especially with respect to tasks that can be performed on-line. Nowadays 
the use of telepathology methods could eliminate the need for circulating histology slides by 
post to expert reviewers. 
3.4.4. Data storage. 
In MRS trials, data processing, data collection and analysis, as well as QC are usually 
centralized (3,7,20) and performed by experts at a coordinating institution. In contrast, in 
trials of pattern recognition MRS (2,8) (see section 2.6), we find the opposite: a centralized 
database that allows asynchronous and remote data entry, editing, download and monitoring. 
Although the development of an automated database is challenging, if the QC protocols and 
measurements are properly implemented and coupled to automated processing and display 
(e.g. MRS visualization tools), these processes can be performed remotely, saving expert time 
and avoiding bottlenecks. A centralized database can also store metadata, e.g. the instrument 
manufacturer, magnetic field, format, or SNR of each MR spectrum. This approach has been 
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successfully used (2,19) However, universal, automated, offline MRS data processing and 
display is still not possible, particularly for MV 2D and 3D MRS as well as their co-
registration with MRI. 
It is important to have all the data collected by the trial stored in the trial’s database instead of 
discarding cases that do not fulfil inclusion criteria, since partially-compliant data can be used 
in secondary analyses or pilot studies. In a database, therefore, one does not exclude data, but 
rather established metrics for the number of “usable” cases and the percentage of cases not 
passing the QC thresholds for each data type. Such metrics allow the creation of subsets of 
data to answer different questions, ranging from data monitoring to analysis.  
A further refinement is to have a distributed network of databases at each clinical center, each 
of which can be searched by the other centers. This approach was tested during the 
HealthAgents project  (21), and despite its attractiveness, disadvantages became apparent.  
Extensive security measures had to be implemented to prevent leaks of sensitive patient data; 
also the hosting and maintenance costs for the whole system were higher than for a 
centralized database. 
2.5 Obstacles that inhibit clinical trials of MRS  
There are two main obstacles that inhibit the development of clinical trials of MRS.  The first 
is the lack of any tradition for sharing data as a prerequisite for publishing MRS studies. As a 
consequence, there is a lack of consensus concerning data acquisition methods, processing 
protocols and output formats, particularly for MV data. There is also a lack of universal 
(either current or legacy formats), automated and standard methods for data processing, 
visualization and exchange, although programs such as 3D-i-CSI (22,23), LCmodel (24) and 
jMRUI (25) are able to process many formats, and ultimately SIVIC (26) can deal with some 
DICOM implementations. 
The second obstacle is the rapid technological advance in MR mentioned in the “logistic 
challenges” section. Accrual of large multicenter datasets requires years (3,8), and for this, a 
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stable set of machines and sequences is needed: the benefit of using newer techniques for 
MRS acquisition need to be evaluated against the problems that will rise by modifying the 
method of observation in the middle of a trial.  Of course, one could argue that a useful MRS 
method has to be able to function across a wide range of instruments, operating systems and 
pulse sequences, and the PR methods developed during the INTERPRET project, for instance, 
were able to “ignore” such technical differences and still successfully classify the tumor 
spectra.  In most clinical trials, however, one will be attempting to minimize technical 
differences between the instruments and their software in order to test a hypothesis related to 
a medical condition. 
2.6. Special issues in multicenter trials involving pattern recognition (PR) 
Trials that incorporate PR methods in the analysis phase have particular features that 
determine their design and logistics.  First, one needs a representative, non-biased sample of 
the population or disease of study, which is the main reason for scaling up to a multicenter 
trial. As in many biomedical domains, this need encounters two constraints:  the “curse of 
dimensionality” and the “curse of data sparsity” (27). The number of features (points) in an 
MR spectrum will be in the thousands whereas the number of samples will typically be 
around 10-30 in the case of single-center studies on cancer. For instance, glioblastoma, the 
most common brain tumor, has an annual incidence-rate of 3.19 per 100,000 according to 
CBTRUS (28), oligodendroglioma is in the 0.26  per 100,000 range and lymphoma in the 
0.44 per 100,000 range. The 304 cases in the multicenter INTERPRET database (19) include 
SV MRS spectra at short TE of 86 glioblastomas, 7 oligodendrogliomas, and 10 lymphomas, 
the latter two illustrating the curse of data sparsity. 
The second requirement is similar to any other trial involving MRS. A series of controls must 
be performed to ensure that the acquired data are representative of the study population from 
both instrumental and clinical quality points of view. In particular, the datasets must not 
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include any artefactual data (
 
Figure 1) or wrongly labelled cases (Error! Reference source not found.Figure 3.) that 
would add unnecessary noise to the natural variability in the study population.  
In order to perform PR analysis of MRS data, MR scientists nowadays have the choice either 
to use an existing software package (Matlab, R, Simca, or SpectraClassifier (29) among 
others) or to collaborate with PR specialists. PR specialists will generally  expect to receive a 
“clean” data matrix with hundreds of data belonging to equally distributed classes (which is 
not normally the case as we have seen) with any bad-quality data removed, and with each 
spectrum labelled according to the disease, disease status or outcome variable of interest. In 
short, a file in which the rows are the cases or measurements and the columns are the 
variables (peak heights or integrated peak areas). Most PR trials have used the whole “raw” 
spectrum instead of integrated peaks. This simplifies the trial by removing the need for expert 
spectroscopist participation before data upload, which as we have seen is a major cause of lost 
data.  More importantly, it eliminates the need for expert assignment and quantification of 
spectral peaks when the method is being used in clinical practice. 
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3. ACHIEVEMENTS OF MRS TRIALS 
3.1. Proton spectroscopy: Multicenter trials involving pattern recognition (PR)  
The INTERPRET database continued to be maintained after the project finished. This fact allowed 
two other multicenter trials (eTUMOUR(2) and HealthAgents(21)) to use the data already acquired 
and validated for the further development of classifiers. Those new classifiers were then validated 
using prospectively acquired spectra. From the PR point of view, the single most important result of 
these three trials is the demonstration that classifiers for SV data at 1.5T can distinguish robustly 
between the most common human brain tumor types with >90% accuracy. In this context, robustness 
means that spectra are still correctly classified if they have been acquired under slightly different 
acquisition conditions, for example with PRESS or STEAM sequences, or with differences in TR and 
TE, or instrument manufacturer (8). Due to the time span for acquisition of data (1994-2008), the 
classifiers can also be considered insensitive to scanner models, operators and even magnetic field up 
to 3T (30), although the latter was only tested on a small dataset.  
The classifiers developed for the most common tumor types have been validated from many points of 
view (31). For internal validation, classifiers were trained and tested with different datasets (1,8). For 
temporal validation, classifiers developed with data from one multicenter project were shown to 
perform well when tested against data acquired during another multicenter project years later (9,32). 
For external validation, these classifiers and their associated decision-support system were also found 
to perform well with prospectively acquired data, not necessarily from the same classes used to train 
the classifiers.  Throughout these tests the results from the classifiers significantly improved 
radiologists’ predictions about tumor type as compared to the use of MRI alone(33-35).  All the 
acquisition, processing and validation criteria developed in these trials are applicable to future 
multicenter projects.  
The classifiers developed during these trials were only for the most common tumor types. To date, it 
has not been possible to classify many of the brain tumor types in the World Health Organization 
(WHO) classification. This is due both to data sparsity and also to the similarity of some of the 
spectral patterns.  Another issue is that the main multicenter results are SV spectra obtained at 1.5T.  
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Furthermore, MV processing, co-registration and output, even at 1.5T, are still not yet manufacturer 
independent.  Table 5 gives some recommendations for future trials, from lessons learned with these 
trials. 
Table 5 near here 
3.2. Phosphorus spectroscopy: The Cooperative Group of MRS Applications in Cancer 
(CoGMAC)  
This trial was performed under an NIH-funded international cooperative program. Using MV 
31
P 
MRS in vivo, it demonstrated in newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients 
that the pretreatment tumor phosphomonoester (PME) values (i.e., the sum of phosphocholine and 
phosphoethanolamine), when normalized by nucleoside triphosphates (PME/NTP) values identified 
patient groups with significantly different treatment outcomes (i. e. treatment response at six months 
and time to treatment failure,TTF) with high effect size (36).  
Differences in the mean tumor value of the pre-treatment PME/NTP were determined, using an 
independent-samples t-test, in DLBCL patients who exhibited either complete (CR) or not complete 
(NCR) response after six months of treatment (37). The mean PME/NTP was 1.44 (standard 
deviation, SD=0.43; n=18 subjects) in CR patients and 2.24 (SD=0.57, n=14) in NCR patients, with a 
highly statistically significant difference (p < .0001), and a large effect size (d = 1.59). A Fisher’s 
exact test was also conducted to determine association between the pretreatment PME/NTP values 
and response to treatment at six months (CR vs. NCR). There was a statistically significant association 
(p < .004) between the pretreatment PME/NTP and the response to treatment. Overall success rate 
was 78.1% (sensitivity=57.1%; specificity=94.4%; positive predictive value=88.9%; and negative 
predictive value=73.9%).  
Kaplan-Meier survival analysis was also conducted to compare DLBCL patients set apart into groups 
with low (> 2.2) or high (≤ 2.2) PME/NTP value for their likelihood to predict TTF. Participants in 
the low PME/NTP group had a median TTF of 66.5 (95% confidence interval, CI=32.9 to 100.1) 
months. This was longer than the high PME/NTP group, which had a median TTF of 6.8 (95% CI=5.2 
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to 8.1) months. A log rank test was conducted to determine if there were differences in the survival 
distributions for the different groups. The survival distributions were statistically significantly 
different (2(1) = 14.43; p < .0005).  
RELATED ARTICLES  
Emrstm1484, emrstm1496. 
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TABLES AND CAPTIONS  
1. Prospective study. 
2. Large patient population (n>50 or power calculations to demonstrate that the size is sufficient). 
3. Quantitative analysis. 
4. Formal criteria for diagnosis (i.e. ROC). 
5. Multiple blinded analyses. 
6. Confirmation of MRS results (i.e. biopsy or out- 
7. Provide sensitivity and specificity measures. 
8. ‘Added value’ diagnostic enhancement over routine CT, MRI, SPECT or PET. 
9. Examine impact on diagnostic thinking (patient management). 
10. Examine impact on choice of therapy. 
Table 1. Common factors for a study on MRS that fulfills EBM criteria. 
PARAMETER STEAM (SHORT 
TE) 
PRESS (SHORT TE) PRESS (LONG TE) 
TE 20 ms (20 – 32 ms) 30 -32 ms (30-32 ms) 136 ms (135 – 144 ms) 
TR 2000 ms (1600 – 2000 
ms) 
2000 ms (1600 – 2000 ms) 2000 ms (1600 – 2000 ms) 
Volume 4 – 8 cm3  4 – 8 cm3 4 – 8 cm3 
Number of averages metabolites 256 192 - 128 192 - 128 
Number of averages water 8 to 32 8 to 16 8 to 16 
Number of points 512 [Philips] 
1024 [Siemens] 
2048 [GE] 
512 [Philips] 
1024 [Siemens] 
2048 [GE] 
512 [Philips] 
1024 [Siemens] 
2048 [GE] 
Bandwidth 1000 Hz [Philips] 
1000 Hz [Siemens] 
2500 Hz [GE] 
1000 Hz [Philips] 
1000 Hz [Siemens] 
2500 Hz [GE] 
1000 Hz [Philips] 
1000 Hz [Siemens] 
2500 Hz [GE] 
Dummy scans 4 4 4 
Table 2. Consensus INTERPRET acquisition protocols (8) for new data with ranges used for retrospective data 
accepted into the database. TE and TR ranges used for retrospective data are given in parentheses. 
21 
 
 
ORDER IN 
WHICH IT WAS 
PERFORMED 
PROCEDURE 
1st Lineshape correction and zero order phasing using water reference with the Klose method  
2nd 0.8 Hz exponential line broadening 
3rd Processing by FFT 
4th Water removal by HLSVD: 5 components removed within ±0.37 ppm of water resonance 
5th Residual water suppression: points at 4.2 to 5.1 ppm set to zero 
6th Linear interpolation to 512 points over 1000 Hz of Siemens and Philips data 
7th Spectrum alignment: maximum of choline peak shifted to 3.21ppm 
8th Normalization of spectrum to Euclidian norm of peak heights 
Table 3. Consensus data processing into the INTERPRET canonical format (8) for spectrum display and analysis. 
 
Trial 
DATA 
TYPE 
PROCESS PARAMETERS ACCEPT IF 
INTERPRET 
and 
eTUMOUR 
SV Automatic 
Water linewidth (WLW): half-height linewidth of the water peak 
of the unsuppressed water spectrum  
WLW  < 8Hz 
INTERPRET 
and 
eTUMOUR 
SV Automatic 
Signal-to-noise ratio (SNR).  
Signal = Maximum metabolite signal in range 0 – 3.4ppm; Noise 
= standard deviation noise in range 9 – 11ppm. SNR = 
Signal/Noise 
SNR > 10 
INTERPRET SV Expert-based 
Possible artefacts that cause rejection: high scalp lipids; poor 
phasing; large baseline artefacts; metabolite peaks of suspect 
origin 
2 experts out of 3 
agree 
eTUMOUR SV Expert-based 
Excellent: Narrow lines, high signal-to-noise, flat baseline and 
no artefacts. 
Good: only 2 of the above and no artefacts. 
Poor: only one of the above and no artefacts. 
Unacceptable: Artefacts and /or outside criteria WLW<8 Hz and 
SNR>10 
2 experts out of 3 
agree 
eTUMOUR MV Expert-based 
Excellent: At least 2 of the following: narrow lines, high SNR, 
flat baseline; and no major artefacts in >80% of voxels 
Good: 50% - 80% of voxels are excellent 
Poor: < 50% of voxels are excellent 
Unacceptable: Less than a 4x4, 5x3 or 3x5 voxel region are 
usable 
Additional reasons for bad quality: Poor SNR, Poor Water 
Suppression, Scalp Artefacts, and too Few Usable Voxels. 
2 experts out of 3 
agree 
eTUMOUR HRMAS Expert-based 
Grading: Excellent, Good, Poor, And Unacceptable.  
Reasons for bad quality: Contamination from Ethanol, 
Contamination from Acetone, Contamination from Mannitol, 
Contamination from Other Substances, Low SNR, Low 
Metabolites, Split Peaks, Negative Peaks, Truncation, 
Insufficient Water Suppression, Rotation Speed Side Bands,  
Unphaseable, Poor resolution 
2 experts out of 3 
agree 
Table 4. Consensus QC of SV data in INTERPRET (8) and SV, MV and HRMAS in eTUMOUR (2). 
 
Reccomendations  
1. Build from previous experience. Work done at lower magnetic fields can help to define more precise 
clinical questions 
Successful strategies used in the past should be applied again and 
those that do not work should be eliminated 
2. Standardize. Protocols for: Acquisition, processing, quality control and data 
exchange 
Define the minimum set of information needed for quality control 
and for reporting an experiment 
3. Automate spectral processing.  Saves expert time 
Avoids expert bias. 
4. Share data. The same data can be analyzed in different ways 
Favors reproducibility of research results 
5. Keep logistics simple. Avoid centralizing procedures on one single expert, especially for 
quality control 
Avoid too many different protocols but accept a certain degree of 
flexibility as long as it provides a reasonable number of good quality 
data 
Table 5. Summary of reccomendations derived from lessons learned in past pattern recognition trials. 
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FIGURES AND CAPTIONS  
 
Figure 1. SV 1H brain tumor spectra at 1.5T from the INTERPRET database, after being processed with the latest 
INTERPRET pipeline ((32) except that the residual water region has not been set to zero). The Y axes are in 
arbitrary units after Euclidean norm. Spectra were acquired with the INTERPRET protocol (8). Voxel sizes for these 
cases were between 1 and 3.375 ml. Identification number (ID). The spectra have been reprocessed for this figure and 
only 0-7 ppm are displayed for visualzation purposes.  
A): ID=I0301/svs000/idf0001: Bad SNR and bad WLW (see Table 4 for definitions of SNR and WLW), STEAM, 
TE=20 ms, SNR=5.61, WLW=29.22 Hz. Acquired in 1997. 
B) ID I0100/svs000/idf0002: Bad SNR and good WLW: STEAM, TE=135 ms, SNR=5.92, WLW=2.75 Hz. Acquired in 
1997. 
C) ID=I0230/svs000/idf0000: Good SNR and bad WLW, STEAM, TE=135 ms, SNR=8.38, WLW=21.59 Hz. Acquired 
in 1994. 
D) ID I1161/svs000/idf0000: Good SNR and good WLW, STEAM, TE=30 ms, SNR=93.32, WLW=2.29 Hz. Acquired 
in 2001. 
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Figure 2.  31P MR spectral set of an individual diffuse large B-cell lymphoma patient. Column A under “Original 
Data” show low-resolution MR images (obtained with a surface coil) overlaid with the grid of volumes of the spectral 
dataset. The images also show 9 highlighted volumes matching with the lymphoma mass. Column B shows the spectra 
corresponding to the highlighted volumes in the images. Panel C expands spectrum 9 of column B, which has the 
largest tumor component, to show its quality and peak assignments. PME, phosphomonoesters including 
phosphocholine and phosphoethanolamine; Pi, inorganic phosphate; PDE, diphosphoester region where also 
phospholipid resonate; PCr, phosphocreatine, small in this spectrum but the largest signal in muscle (i.e., spectra 2, 3, 
and 5 in column B); NTP the , , and  signals of nucleoside triphosphates.  Columns D and E under “Principal 
Component Analysis” show the principal components (PC’s) and associated scores obtained by the analysis. Column 
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D shows that 89.9% of the variance is included in the first two PC’s. The addition of these first two PCs yielded a 
clean “global muscle component” while subtraction yielded a clean “tumor component” as shown in the columns F 
and G under “Matrix Manipulation”. Further, matrix inversion and multiplication to eliminate the muscle 
component allowed analysis of the percent contribution of tumor in each spectrum (column H, “Tumor 
Reconstruction”. Compare spectrum 5 in columns B and H where a strong muscle component (column B) obscured a 
small but important tumor contribution in the spectrum (column H). Similar results were obtained by analyzing only 
the nine spectra shown in the figure, a subset of 30 spectra around the tumor region, or the total dataset of 512 
spectra. 
 
 
Figure 3. : Anaplastic astrocytoma (case I0456 from the INTERPRET project (8)), processed with the automated 
software developed. Note that it is not only important to know the type of disease the spectrum corresponds to but 
also the importance of a proper annotation of the location and other metadata: the spectrum in A is not comparable 
to the one on B in terms of pattern, although they both belong to the same patient and pathology. A was recorded well 
into the cystic liquid while C was acquired in the tumor margins. B was acquired in the margins of the tumor but at a 
different echo time (short). 
A) Top, reference image with voxel location inside cystic lesion. PRESS, TE=136 ms, STR=2000, SNR=12.17, 
WLW=2.52 Hz. 
B) Top, reference image with voxel location on tumour margin. PRESS, TE=30 ms, STR=2000, SNR=59.99, 
WLW=3.43 Hz 
C) Top, reference image with voxel location on tumor margin. PRESS, TE=136 ms, STR=2000, SNR=16.64, 
WLW=2.06 Hz. 
SNR and WLW calculated as in Figure 1. Y axis in arbitrary units as in Figure 1. X axis, in ppm. NAC, N-acetylated 
compounds (38). 
 
